Raziel Green, 52, an active runner and mother of two, was diagnosed with a rare form of ALS in 2017. Since starting a ...
A Regina mother who was one of the first ALS patients to test a new treatment is now celebrating its accelerated approval in ...
Among participants who met the core RESTORE-ALS Trial criteria (e.g., baseline serum NfL > 33 pg/mL, TRICALS risk score range between –6.5 and –2.5, baseline slow vital capacity > 60%, and symptom ...
In this episode, Tylah Tully gives the skinny on Neurizon Therapeutics (ASX:NUZ) HEALEY ALS Platform Trial, as the company ...
AKGsOVIHAMS, a leading healthcare institution, has marked progress in treating ALS using integrative medicine. Known for combining conventional and alternative therapies, the institute has shown ...
Noon, is tackling ALS and other neurological disorders with a bold, multi-targeted approach. Fueled by a personal encounter ...
Woolsey Pharmaceuticals has secured additional funds to continue advancing its ROCK inhibitor Bravyl (oral fasudil) for the ...
Columnist Dagmar Munn says she has often felt out of place in the ALS community because of the slower pace of her disease ...
Clene (CLNN) and its subsidiary, Clene Nanomedicine announced new evidence from a cross-regimen, post hoc analysis of long-term survival in ...
HotCopper on MSN6h
'Maximising the potential': Neurizon prepares for HEALEY study of ALSNeurizon Therapeutics (ASX:NUZ) has shared an update on its preparations for its HEALEY ALS Platform Trial – a multicentre, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback